10 (41), 2014

-

2

10

(41)

, 201

4

..1,2, ..1,21 - - , .2 , .

() 17,5 . [13]. , 2012 . 761,3 100 . . () 49,3% 35,3%, , 84,6% 23,9% [6].

. - , - 2006 . 2005 2011. - 30,4%. , - : 2018 . 649,4 100. [30].

- (), -. 2002. 6,2 . , - 2002 2011 . 8 . [7]. - - -

. , - , - (), 25%. - - - , - , , 69% , , 77% 77% - .

, - - , , 50% - [13]. .

- , - ,

. - , -- - (), , -. - [3, 4, 15]. - . [11] - , - , , - . - - .

3

10

(41)

, 201

4

- .

- - - . [1] , 50% - -, 20% (), 90% - , 10% . - -- . , -, , , , , .

- , - . , - , , -, -, , - [11].

- - , -- , - . - - , , . -

- , . , - - , , -. - -, , -, , -- . , [11].

- . - II ( II) - ( -). , .

-

, , -, .

-- -, , - 1- (1-), - II (-, , NADPH-, - , -, - ) [20]. , - - g- (PPAR-g-), -

- [21]. - , . , PPAR-g- - , . - - , , , [19]. , - . , .

- , - -. - , - , -, , [31]. - -, - . - -. , , [27]. - ZO-1 ( ), - .

4

10

(41)

, 201

4

, -, II -. TRANSEND - . - [24].

- - : - (NO) , - - . - -, . - -

NO , - . - - , - 2, - NO. - , - . - - [29]. - -

, - .

- - -, , : -- - (- , -), - [10, 25]. -, - - ,

1.

5

10

(41)

, 201

4

- [2].

, -, . , - 1-, (. 1) [32]. 4550%, 6490%, - . -, (93 99% ). - 57- [26], 78- [18]. - , 24 ., : - 3550. , - 20. - , 98% , , .

- - 60% , 10% . - , . - , -, -, [10].

, - . . - -. - , . - . , - , .

8- T. Littlejohn - (: 0; 20; 40 80) (: 0; 2,5; 5 10)

2. [34]

- 12- - ( >100..).

- - (. / 26,5/21..) 80 - 10 . (

6

10

(41)

, 201

4

. , , - 2 . 5 80 8 , 40 - 4, 8 12- [8]. - - : 80 8 , - 5 -, 40 12- - - , - [9].

- - . - [12]. , - 13 542 - , - - [16]. , - -

, - - - [14]. - - - [25].

- . - -, - . - - , . - : 18% -

10 11% T80/A10. 5 40 80 2,4 2,8% . - , , 2% [35] (.3). , - , ( - , ), - . , , - .

3. - , 10, , 5 [35]

1. .., .., .. . - . . . 2013; 7, 9 (1):414.

2. .. - : . Cons. Med. 2011; 13(10):959.

3. .. . . . 2013; 9(6):66477.

4. .., .. 2013 : , , . . 2013; 12:8395.

5. .., .. , . . 2013; 10:7181.

6. .., .. : . . . 2012; 11(1):510.

7. .., .. 20022012. . . 2013; 2:411.

TWY.

KZ.

2014

.02

7

10

(41)

, 201

4

8. BekkiH., YamamotoP., SoneM. et al. E cacy of combination therapy with telmisartan plus amlodipin in patient with poorly controlled hypertension. Oxid Med Cell Longer 2010; 3(5):3426.

9. BekkiH., YamamotoP., SoneM. et al. Bene cial cardiomethabolic action of telmisartan plus amlodipin therapy in el-derly patient with poorly controlled hypertension. Clin Cardiol 2011; 34(4):2615.

10. BilleckeS.S., MarcovitzP.A. Long-term safety and e cacy of telmisartan/amlodipine single pill combination in the treat-ment of hypertensior. Vasc Health Risk Manag 2013; 9:95104.

11. ESH/ESC Tasc force for the managerment of arterial hypertension. 2013 practice guidelines for the management of arterial hypertension of the Europian Society of Hypertension (ESH) and the Europian Society of Cardiology (ESC). JHypertens 2013; 31192538.

12. FogariR., DerosaG., ZoppiA. et al. E ect of telmisartan-amlodipine combination at di erent doses on urinary albumin excretion in hypertensive diabetic patient with microalbuminuria. Am JHypertens 2007; 20(4):41722.

13. GoA.S., Moza arianD., RogerV.L. et al. Heart disease and Stroke statistics-2012 update: a report from the American Heart Association. Circulation 2013; 127: e6e245.

14. GuthrieR.M., DahlofB., JamersonK.A. et al. E cacy and tolerability of telmisartan plus amlodipine in added-risk hy-pertensive patient. Curr Med Res Opin 2011; 27(10):19952008.

15. James P.A., Oparil S., Carter B.L. et al. Evidence-Based Guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee. JAMA 2014; doi:10.1001/jama.2013.2844

16. MaL., WangW., ZhaoY. et al. Combination of amlodipine plus angiotensin receptor blocker of diuretics in high-risk hypertensive patient: a 96-week e cacy and safety study. Am JCardiovas Drugs 2012; 12(2):13742.

17. MallatS.G. What is a preferred angiotensinII receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovas Diabetology 2012; 11:32.

18. MeredithP.A., EliottH.L. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22(1):2231.19. MesserliF.H. Evolution of calcium antagonists: past, present and future. Clin Cardiol 2003; 26(Suppl.2):11126.20. MiuraS., KarniaS.S., SakuK. Review: angiotensinII typeI receptor blockers: class e ects versus molecular e ects. JRe-

nin Angiotensin Aldosterone Syst 2011; 12(1):17.21. MoriH., OkadaY., AraoT. et al. Telmisartan at 80mg/day increases high-molecular-weight adiponectin levels and im-

proves insulinresistance in diabetic patients. Adv er 2012; 29(7):63544.22. NeldamS., EdwardsC., LangM., JonesR. Long-term tolerability and e cacy of single-pill combinations of telmisar-

tan 4080mg plus amlodipine 5 or 10mg in patients whose blood pressure was not initially controlled by amlodipine 510mg: Open-label long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studies. Curr er Res Clin Exp 2012: 73(12):6584.

23. PittB., BuingtonR.P., FubergC.L. et al. E ect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigators. Circulation 2000; 102:150310.

24. RipleyT.R., HarrisonD. e power to TRANSCEND. Lancet 2008; DOI: 10.1016/SO140-6736(08)61243-X. Available at: www.thelancet.com.

25. SeguraJ., RuilopeL.M. Areview of the bene ts of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydroclorothiazide. Vasc Health Risk Manag 2013: 9:5218.

26. StangerJ., SuC., RothW. Pharmacokineties of orally and intervenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patient. JInt Med Res 2000; 28(4):14967.

27. TomiyamaH., YamatadaJ., KojiY. et al. E ect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetilarginine levels. Am JHypertens 2007; 20:130511.

28. VerdecchiaP., AngeliF., MazzottaG. et al. e renin angiotensin system in the development of cardiovascular diseases: role of aliskiren in risk reduction. Vas Health Risk Manag 2008; 4(5):97181.

29. ZbangX., KichukM.R., MitalS. et al. Amlodipine promotes kininmediated nitric oxide production in coronary vac-rovessels of falling human hearts. Am JCardiol 1999; 84:271331.

30. - . 2014; old.rosminzdrav.ru/heaith/cardiovascular/97/YakovlevaTV-2.ppt

31. .. . . . . 2011; 10(7):93104.

32. Benson et al. Identi cation of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARModulating Activity. Hypertension 2004; 43:9931002.

33. omasW. Littlejohn et al Original Research: Telmisartan Plus Amlodipine in Patients with Moderate or Severe Hyper-tension: Results from a Subgroup Analysis of a Randomized, Placebo-Controlled, Parallel-Group, 44 Factorial Study. Postgraduate Medicine. 2009; 121(2):514.

34. WhiteW.B., LittlejohnT.W., MajulC.R. et al. E ects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 12 hypertension. Blood Press Monit 2010 Aug.;15(4):20512.

35. NeldamS., MargreetL., RussellJ. Telmisartan and Amlodipine Single-Pill Combinations vs Amlodipine Monotherapy for Superior Blood Pressure Lowering and Improved Tolerability in Patients With Uncontrolled Hypertension: Results of the TEAMSTA-5 Study. JClin Hypertens (Greenwich) 2011; 13: 45966.

Consilium medicum, 16, 5, 2014., . 510.